CHEM BIO MEDICAL DEFENSE 2 FEB 90

File: 121096_sep96_decls38_0001.txt
Page: 0001
Total Pages: 5

Subject: CHEM BIO MEDICAL DEFENSE  2 FEB 90                              

Unit: OTSG        

Parent Organization: HSC         

Box  ID: BX003203

Folder Title: CURRENT CONTINGENCY VACCINES                                                                    

Document Number:          1

Folder Seq  #:        137



                                                                    UNCLASSIFIED


         17 Nov 89. Current contingency vacci ms: EEE, WEE, VEE (Live), VEE (killed), Rift Valley Fever.
         18 May 90. Add anthrax ard botutim toxoid (A-E).


         REVISED ON 2 Feb 90. ME)EP 6T6C DISK.
         Copy with my personal notes on it. re)                                                  DECLASSIFIED
         GOAL: Readiness                                                                         ON: 25 NOV 96
                                                                                                 BY: SEC ARMY (DAMH) UNDER
         PANEL: Equip                                                                            SEC 3.4 EO 12958

         MDEP: 6T6C


         MDEP TITLE: Chem Bio Medical Defense


         MDEP POC: MAJ Eng

         OBJECTIVE: To improve medical defense against chemical and/or biological agents.




                                             ACTION POC/       ACTION REQUIRED/
         TASKS                               OFC SYMB/TEL      DUE DATE                 STATUS


         Procure chm/bio                     MAJ Eng/
         medical defense                     DASG-HCD/
         mteriet:                            756-8163

         QA for vaccines at the Salk Institute                 FY90                     Depends @ Warren Ferguson, 343-7536
         (17 Nov 89. Warren Ferguson said that the contracted awarded in FY89 is enough to carry us out in FY90. Does
         net see that we med to let another contract out. I should inquire about Later in FY90).


         VenezueLa Equi m Encephalitis                         FY89                     IND
           Vacci m
         (FY89 funds will be used to cover OA cost for this vaccine.)

         Anthrax Vacci m                                       FY90                     Commercially Available
         (Was net able to Let contract for $4.5M buy                         oldiers in FY89. Should be able to do so in
     FY90). Nov 89. Anne said that contracting is reluctant to sperd over 33 percent of the original contract for
         additional doses of anthrax vacci m. I told her to go up to the boss and even to the DA comptroller for a
         ruling. If an AR forbids it, then we should go with the 33 percent overage and maybe consider doing another
         contract.
         14 Feb 90. Memo was sent to USAKKDA to go ahead to procure an additional batch                           nthrax.
         Michigan State Dept of Health (Dr. Mitchell) said that they will not be able to      howr the current    contract to
         provide vaccine w a cost reimbursement basis. They will have to negotiate another contract on a          fixed price
         basis. I told Anna to go ahead with the mgotiati ms but expedite the situation as much as possible.

         Same thing will apply to the botutinm toxoid procurement in terms of fix price proposal. Will have to
         negotiate an this contract. Portm Dom is producing                         F & G bot toxoid. There are options t
         buy additional toxoids and for te manufacturer to store and maintain potency. @$iFigqoiqyk,-
         CONUS? ANTHRAX IS LICENSED BY FDA.


         Cmvutsant Antidote Nerve Agent                        FY90                     Transitioned to USAMMDA.
         (LTC Lehmnn said an 4 Oct 89 that should have a contract cut by 4OFY90, even though Stl' is s@mce;ssftjl -in it
         court action against Duphar. We will just let a contract to STI.) Nov 89. Lehmann said that STI Lost their
         bid. But are encountering difficulties because the source of diazepw is in question. Duphar was able to
         trace the original source of diazepam but it my have been mixed in the transfer from intermediate to
         intermediate. FDA cannot certify a source Like that. if we want to make more CANA-S, we must be assured that
         the source of diazepam is the same as what the FDA certified to be able to get the same product. Total buy of
 CANA is $3.6M in two deliveries
         total buy within 180 days). Clinical studies are delayed from Aug 89 to Jan 90. Milestone I
         to Sep 90. 19 Dec 89 update m procurement cost is S3.781H from LTC Lehmm.                 UNCLASSIFIED

Document 5 f:/Week-36/BX003203/CURRENT CONTINGENCY VACCINES/chem bio medical defense 2 feb 90:12069615360339
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003203
Unit = OTSG
Parent Organization = HSC
Folder Title = CURRENT CONTINGENCY VACCINES
Folder Seq # = 137
Subject = CHEM BIO MEDICAL DEFENSE 2 FEB 90
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 06-DEC-1996